Institute of Pathology, Lucerne Cantonal Hospital, Lucerne, Switzerland.
Am J Clin Pathol. 2012 Dec;138(6):837-44. doi: 10.1309/AJCPL5IV0LAWSERG.
This study sought to evaluate a new combined gene and protein detection platform in the context of HER2 evaluation in breast and gastric carcinomas. HER2 immunohistochemistry (IHC) and dual color in situ hybridization (Dual ISH) were combined on a single slide. Results were compared with conventional HER2 IHC and fluorescence ISH. Results from the gene and protein assay were reliable and highly reproducible for both breast and gastric carcinomas. Concordance was found between conventional HER2 IHC and ISH testing and the gene and protein assay in the same laboratory (>95% for Dual ISH; lower for IHC because of different antibody clones), between IHC and Dual ISH performed on the same slide (>92%), and in the gene and protein assays between laboratories (>96%). This cost- and time-effective method provides fast and definitive results (IHC confirmed by means of Dual ISH) to aid in rapid treatment decisions. It can also be applied to other gene and protein combinations.
本研究旨在评估一种新的联合基因和蛋白检测平台，用于乳腺癌和胃癌中 HER2 的评估。HER2 免疫组化（IHC）和双色原位杂交（Dual ISH）在同一张载玻片上联合进行。结果与传统的 HER2 IHC 和荧光原位杂交进行了比较。对于乳腺癌和胃癌，基因和蛋白检测的结果是可靠的，且具有高度可重复性。在同一实验室中，常规的 HER2 IHC 和 ISH 检测与基因和蛋白检测之间具有一致性（Dual ISH 的一致性>95%；由于使用了不同的抗体克隆，IHC 的一致性较低），同一张载玻片上的 IHC 和 Dual ISH 之间具有一致性（>92%），以及实验室之间的基因和蛋白检测之间具有一致性（>96%）。这种具有成本效益且耗时的方法提供了快速和明确的结果（通过 Dual ISH 确认 IHC），有助于快速治疗决策。它还可以应用于其他基因和蛋白组合。
Zotero 插件